A Study of Patients With HER2-Positive Metastatic Breast Cancer
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00105456
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- Signed Informed Consent document (unless the IRB has granted a waiver of consent)
- Signed Authorization for the Use and Disclosure of Health Information document
- HER2-positive breast cancer
- Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment
- Availability of cancer-specific historical data points in the patient's medical records
Exclusion Criteria
- There are no exclusion criteria for participation in this trial
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method